Guy Healing

About Guy Healing

Dr Guy Healing PhD, ERT, FBTS. Guy is an experienced senior toxicologist with expertise in general toxicology and the safety assessment of pharmaceuticals. As a manager of pre-clinical Study Monitors and Study Directors, he is an expert in study design, conduct and reporting. He has excellent interim management skills developed over 20 years in managing teams in a complex global environment. He has served on the BTS Executive Committee for 10 years, is a member of the Panel for the UK Register of Toxicologists and has over 40 publications in peer reviewed journals. Guy brings a pragmatic and collaborative approach to designing and delivering nonclinical studies to time, quality and cost.

Study monitoring – why is it important?

Guy Healing, Senior Toxicologist at ApconiX is interviewed by Jon Clements of Metamorphic PR What is study monitoring and why is it important to drug discovery projects? Pharma companies need to ensure their drugs are safe but also that they work. In drug development this requires numerous studies to be presented to international regulators, and [...]

By |2019-02-06T10:00:33+00:00February 6th, 2019|Nonclinical Study Monitoring|Comments Off on Study monitoring – why is it important?

Differential expression of cyclin-dependent kinases in the adult human retina in relation to CDK inhibitor retinotoxicity

Abstract Cyclin-dependent kinases (CDKs) are a family of kinases associated predominantly with cell cycle control, making CDK inhibitors interesting candidates for anti-cancer therapeutics. However, retinal toxicity (loss of photoreceptors) has been associated with CDK inhibitors, including the pan-CDK inhibitor AG-012896. The purpose of this research was to use a novel planar sectioning technique to determine [...]

By |2019-01-30T12:25:18+00:00January 24th, 2019|Toxicology, Publications|Comments Off on Differential expression of cyclin-dependent kinases in the adult human retina in relation to CDK inhibitor retinotoxicity